bioRxivBioinformaticsPreprint
Can Folding Models Tell Binders from Bluffers? Evidence from POISK: The Patent-Derived Antibody Dataset
Daria Tupikina, Andrea RoncoliiD, Alexander BujotzekiD, Brennan AbanadesiD
Abstract
Structure prediction models are increasingly deployed as zero-shot digital screens in antibody design, operating under the assumption that high folding confidence implies true binding. However, rigorous validation of this premise has been limited by small test sets, narrow target diversity, and the risk of data leakage from training-adjacent structures. Here we introduce POISK: Patent-extracted Organization of Immunoglobulin Sequence Knowledge, a large-scale dataset derived from the US patent literature, comprising 89074 antibody-antigen records extracted from 10110 patents using an LLM-based pipeline. From this resource, we curate a balanced benchmark set of 22494 complexes: 11247 patent-validated binders without a known resolved structure paired with putative non-binders constructed from sequence-similar human repertoire antibodies. Using this dataset, we benchmark six leading structure prediction models (AlphaFold-Multimer, Boltz-2, IntelliFold v2, OpenFold3, Protenix-v1, and Protenix-v2) on their ability to discriminate binders from decoys. The best-performing model, Protenix-v2, achieves 72% pairwise accuracy over all pairs and 87% on the most confident half of predictions, and correctly identifies the true binder from a pool of 50 candidates in 29% of trials; this represents a substantial enrichment over random selection, yet remains far from reliable single-candidate identification. Structural consensus across models also discriminates binders from decoys, with pairwise accuracy reaching 73.1% when three or more models converge on a pose (DockQ>0.23, covering around 54.2% of pairs). Epitope localization remains unreliable: the best model contacts annotated epitope residues in only 62.8% of cases, indicating that binding discrimination does not establish accurate epitope localization. Our results suggest that current folding models provide useful but limited signal for antibody screening and should be complemented by orthogonal methods. We release POISK as a community resource for future benchmarking and model training.
- organism: human
- assay: protein structure
- research focus: benchmarking
- research focus: differential expression
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Challenges in antibody structure prediction
Monica L. Fernández‐Quintero, Janik Kokot, … Klaus Roman Liedl·mAbsPeer-reviewed·Feb 12, 2023
- FoldAbS: Repurposing the Protein Folding Model as a Foundation Encoder for Antibody Screening
Jun Wu, Fandi Wu, … Jianhua Yao·bioRxiv·Nov 5, 2026
- Benchmarking antigen-aware inverse folding methods for antibody design.
Bartosz Janusz, Dawid Chomicz, … Konrad Krawczyk·Bioinformatics AdvancesPeer-reviewed·Jan 1, 2026
- Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies
Jeffrey A. Ruffolo, Lee‐Shin Chu, … Jeffrey J. Gray·bioRxiv·Apr 20, 2022
- Structural Plausibility Without Binding Specificity: Limits of AI-Based Antibody-Antigen Structure Prediction Confidence Scores
Eva Smorodina, Montader Ali, … Victor Greiff·bioRxiv·Mar 3, 2026
- Benchmarking Boltz-2 for Screening of Therapeutic Antibody-Antigen Interactions
Alexandra Fieux-Castagnet, Julian Waton, … Christoforos Anagnostopoulos·bioRxiv·May 14, 2026